Skip to content
NASDAQ · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · LARGE CAP

Incyte Corp. INCY

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$5.1B
▲ 21.2% YoY
$1.3B
▲ 3845.0% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Its global headquarters are located in Wilmington, Delaware, where it conducts discovery, clinical development and commercial operations, and it also conducts clinical development and commercial operations from its European headquarters in Morges, Switzerland, its Japanese headquarters in Tokyo and its Canadian headquarters in Montreal. As of December 31, 2025, it had 2,844 employees. It is organized around three therapeutic areas, defined by the indications of its approved medicines and the diseases for which its clinical candidates are being developed: Hematology, Oncology, and Inflammation and Autoimmunity. Incyte was incorporated in Delaware in 1991.

Written from the business description in INCYTE CORP's annual report to the U.S. Securities and Exchange Commission, filed 10 February 2026. Every sentence was checked against that document before publication.

Growth

USD 5.1B
Revenue, FY2025 · full 17-year series below
Revenue $B Net income $B
FY2025 · Revenue 5.1 · Net income 1.3
2B4B
2009201220152018202120242025
Compound annual growth
+14.8%
+14.0%
+21.2%
+25.5%
+55.7%
+61.6%
+71.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +14.0% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

25 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 29.5% · Net 25.0%
-500%-1000%-1500%
200920172025
ROE
FY2025 · ROE 29.9%
10%20%30%-10%-20%-30%
200920172025
Three returns, three denominators.

Each USD of equity produced 30 cents of profit this year.

Cash & shareholders

USD 0.00
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2022 · FCF 892.1
400M800M-150M-300M
200920172025
Net buybacks $B Dividends $B
FY2025 · Dividends · · Net buybacks 0.0
1B2B
2022202320242025

Total assetsUSD 7.0B
EquityUSD 5.2B
CashUSD 3.1B
Current ratio3.32×

Equity funds 74% of total assets.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
INCY, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B5.14.23.73.43.02.72.21.91.51.10.80.50.40.30.10.20.0
Operating income $B1.50.10.60.60.6−0.30.40.1−0.20.10.1−0.0−0.00.0−0.10.0−0.1
EBITDA $B1.60.20.70.60.6−0.20.50.2−0.20.20.10.00.00.0−0.10.0−0.1
Income tax $B0.40.30.20.2−0.40.10.00.00.00.00.0−0.00.00.0◌◌◌
Net income $B1.30.00.60.30.9−0.30.40.1−0.30.10.0−0.0−0.1−0.0−0.2−0.0−0.2
Free cash flow $B◌◌◌0.90.6−0.30.60.3−0.20.20.1−0.00.0−0.1−0.20.10.0
EPS, diluted $6.410.152.651.524.27−1.362.050.51−1.530.540.03−0.29−0.56−0.34−1.49−0.26−2.06
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————————
ROE %29.90.812.58.429.7−11.419.86.2−30.535.3———————
Shares out B0.200.190.220.220.220.220.220.210.210.190.190.170.160.130.130.12◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 65 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Five checks were skipped: cost of revenue is not tagged before 2012. Two checks were skipped: EPS is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityServices-Commercial Physical & Biological Research
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image